Boston Scientific expects the Farapulse pulsed field ablation (PFA) technology to provide a much-needed competitive edge in electrophysiology, a market where the company lags far behind its most important competitors.
Electrophysiologists and ablation catheter developers expect pulsed field ablation (PFA) to become the dominant cardiac ablation technology in the next decade because it is safer and more efficient than existing ablation techniques